TransCure bioServices is delighted to announce a strategic partnership with Preclina, a leading South Korean preclinical research company renowned for its expertise in inflammatory diseases. This collaboration holds immense significance as it enables us to better cater to our clients in South Korea and the broader Asian region.
Preclina, a non-clinical CRO situated in South Korea, specializes in autoimmune and inflammatory disorders such as NASH, fibrosis, arthritis, and scleroderma. Boasting an extensive background in immunology, patient-derived cells, and animal models, their fully-integrated drug discovery platform has made them an indispensable partner for clients developing novel drugs and diagnostic/treatment technologies. Preclina’s core values encompass excellence, innovation, and a steadfast commitment to customer satisfaction.
The alliance between TransCure bioServices and Preclina amalgamates the expertise of both entities, offering more comprehensive and effective preclinical research services. This collaboration not only expands our portfolio of services, but also bolsters our expertise and research results. Furthermore, this partnership significantly reinforces our standing in the South Korean preclinical research market.
We take great pride in joining forces with Preclina to provide our clients with an expanded array of superior-quality services. With this exciting new venture underway, we look forward to exploring the numerous opportunities it presents for growth and innovation.